Background: Serum cardiac troponin T (cTnT) concentrations may be increased in patients with renal dysfunction without evidence of cardiac damage, as assessed by conventional methods. It has been suggested that these positive measurements result from the expression in skeletal muscle of fetal isoforms of cTnT, which are detected by the cTnT immunoassay. Methods: Skeletal muscle (exterior oblique) biopsies were taken from healthy living kidney donors (n ‫؍‬ 5) and transplant recipients (n ‫؍‬ 19). The amounts of cTnT and creatine kinase (CK) isoenzymes in skeletal muscle of healthy controls were compared with those in patients with renal failure (Wilcoxon-Mann-Whitney test). cTnT was measured quantitatively by a secondgeneration assay, with a limit of detection of 1 g/g of protein, and qualitatively by immunohistochemistry and immunoblotting. CK-MB was measured by quantitative electrophoresis. Results: Minute quantities of cTnT were detected in 2 of the 5 (40%) control samples and 9 of the 19 (47%) renal failure samples, respectively, at mean concentrations of <5 g/g of protein for both subject groups. This was <1/6000th that found in heart muscle. There was no significant difference in cTnT or CK-MB content in skeletal muscle between healthy controls and patients with renal failure. Increased serum cTnT did not predict detectable cTnT in skeletal muscle. cTnT was not detected qualitatively by immunoblotting or immunohistochemistry in any skeletal muscle samples.
Studies in which serum concentrations of cardiac troponin I (cTnI) 5 and T (cTnT) have been measured in patients with acute coronary syndromes have shown that even marginally increased concentrations are important predictors of short-and long-term mortality (1, 2 ) . It is now well recognized that in North America (3, 4 ) and Europe (5 ), cardiovascular risk, and specifically cardiac risk, is increased in patients on dialysis. The diagnostic and prognostic utility of the serum markers of myocardial damage, cTnT and creatine kinase MB isoenzyme (CK-MB), has been questioned within this patient group because a study has described increased serum concentrations of these markers with no apparent signs of cardiac damage (6 ) .
It has been suggested that cTnT and CK-MB are expressed by diseased skeletal muscle found in patients with chronic renal failure (CRF) (7 ) . It has been shown that myopathy (8, 9 ) and impaired exercise tolerances (10, 11 ) are associated with CRF and dialysis. An electron micrographic study has demonstrated evidence of muscle regeneration in biopsies of skeletal muscle taken from patients with CRF (12 ) .
There is evidence that in regenerating muscle, CK-MB expression is increased (13 ) and cTnT is expressed; examples include rat skeletal muscle in response to injury and denervation (14 ) , human Duchenne muscular dystrophy (DMD) (15 ) , and the C2C12 mouse myocyte cell line (16 ) .
In cardiac myocytes, cTnT is encoded by one gene, but four possible isoforms may be produced by alternative splicing (17 ) . These isoforms are present in developing skeletal muscle and are down-regulated after birth (18 ) . The B subunit of CK is similarly expressed in relatively larger amounts in developing skeletal muscle. Isoforms of cTnT and increased amounts of CK-MB have also been detected in diseased skeletal muscle (6, 15 ) . If released into the circulation, these isoforms could potentially be detected in serum by the cTnT immunoassays, producing falsely increased or spurious cTnT values, which may be wrongly interpreted as evidence of myocardial damage. This misdiagnosis could be particularly important in patients with CRF with regenerating skeletal muscle. In healthy adult skeletal muscle, these cTnT isoforms are completely down-regulated; thus, the problem of false positives should not arise with adults without skeletal myopathy. The controversy of false positives and cTnT associated with regenerating skeletal muscle has not affected use of cTnI as a marker of myocardial damage. In contrast to both CK-MB and cTnT, Ricchiuti et al. (7 ) have stated that cTnI is not expressed during any stage of skeletal muscle development. In addition, cTnI immunoreactivity has been shown to be absent from diseased regenerating skeletal muscle (19 ) . For this reason, the subject of cTnI in skeletal muscle has not been addressed in this study.
In patients with CRF, however, it is unclear whether cTnT isoforms detected in serum are derived from skeletal muscle or result from myocardial damage (7 ). It was, therefore, the aim of this study to relate cTnT detected in skeletal muscle to cTnT detected in circulation. We measured muscle cTnT quantitatively and qualitatively, using two different qualitative techniques. In addition, we investigated the effect of uremia on CK-MB activity in skeletal muscle.
Materials and Methods
We attempted to quantitatively detect abnormal amounts of cTnT-like immunoreactivity and CK-MB activity in skeletal muscle samples taken from patients with end stage renal disease (ESRD), comparing the findings with those from skeletal muscle samples from healthy controls and cardiac muscle samples. In addition, we measured cTnT expression qualitatively in muscle sections by immunohistochemistry and by immunoblotting using the monoclonal antibodies M7 and M11-7, which are used in the Roche second-and third-generation assays for cTnT. These antibodies, M7 and M11-7 (Roche), bind to epitopes six residues apart, specifically found only on the cTnT molecule (20 ) .
human muscle samples
Samples of the exterior oblique muscle were taken from patients with ESRD during elective renal transplant surgery. Samples were obtained over a period of 1 year from patients (n ϭ 19) receiving either cadaver or live-donor kidneys. Control samples of the same muscle were obtained from live related kidney donors (n ϭ 5). Human cardiac tissue was obtained from left atrial appendage (LAA) samples (n ϭ 6) obtained from explanted hearts taken during cardiac transplant surgery. The cardiac transplant patients were all diagnosed as having dilated cardiomyopathy. Muscle samples were split into two portions, frozen in liquid nitrogen, and stored at Ϫ80°C until use. Serum samples were obtained from all patients at the time of renal transplant surgery. Approval was obtained from the local research ethics committee of St. George's Hospital, and consent was obtained from all patients.
The median age of the patients with ESRD (7 males and 12 females) was 51 years (range, 36 -65 years). All 19 patients were hypertensive, 6 were diabetic, 8 had hyperlipidemia, 5 smoked, and 2 were ex-smokers.
preparation of muscle samples
Muscle samples were coarsely ground in liquid nitrogen with a mortar and pestle over dry ice. The coarse powdered muscle was then split into two aliquots; one aliquot was homogenized for immunoblotting, and the other was homogenized for the measurement of tissue content of cTnT, CK, and CK isoenzymes. The other frozen portion, collected at the time of surgery, was retained for immunohistochemical analysis.
preparation of cytosolic and myofibrillar fractions for assay of ck and cTnT Cytosolic and myofibrillar extracts of muscle samples were prepared according to the method of Bodor et al. (19 ) . Approximately 30 mg of coarsely ground muscle powder was homogenized in 3 mL of 0.05 mol/L Tris buffer (pH 7.4) in an Ultra-Turrax homogenizer (Merck). The homogenate was incubated for 1 h at 4°C and centrifuged at 100 000g for 1 h. The supernatant was retained, and the pellet was resuspended in 3 mL of 0.05 mol/L Tris buffer. This process was repeated twice to produce a cytosolic fraction. The three aliquots containing the cytosolic fraction were then pooled, aliquoted, and stored at Ϫ80°C until analysis for CK, CK isoenzymes, cTnT, and total protein. The pellet remaining after the last centrifugation (containing the myofibrillar proteins) was resuspended in 3 mL of 0.05 mol/L Tris (pH 8.0) containing 8 mol/L urea, 1 mmol/L CaCl 2 , and 15 mmol/L ␤-mercaptoethanol. This suspension was incubated for 1 h at room temperature and then centrifuged at 20 000g for 30 min. The supernatant was retained, and the pellet was resuspended in 3 mL of the same buffer. This process was repeated twice more to extract the myofibrillar fraction. The three aliquots of myofibrillar fraction were pooled.
Urea was removed from the myofibrillar fraction by use of a PD-10 sample preparation gel exclusion cartridge (Amersham Pharmacia Biotech), in accordance with the manufacturer's instructions; the eluent was Tris buffer without urea. This solution was then used for the analysis of cTnT, CK, CK isoenzymes, and total protein concentrations.
measurement of ck isoenzymes and cTnT
Total CK activity was measured quantitatively by the N-acetylcysteine activated (Roche) method on a Cobas Mira (Roche) analyzer at 37°C. Cytosolic extracts were used to measure CK isoenzymes, which were separated and quantified by agarose gel electrophoresis in the Rapid Electrophoresis system (Helena Laboratories). cTnT was measured by the second-generation Enzymune method, performed on an ES300 analyzer (Roche). The lower limit of detection for this assay has been reported as 0.01 g/L, with a functional sensitivity (between-assay CV ϭ 20%) of 0.05-0.1 g/L (20, 21 ) . This lower limit of detection is comparable to that of the newer assay in current use (third generation), although the reproducibility of the newer assay has been improved at lower concentrations. According to the manufacturer's package insert, good correlation has been shown between the second-and third-generation assays at concentrations of 0.02-20 g/L (r ϭ 0.98).
We diluted all heart cytosolic and urea-free myofibrillar fractions before analysis to a concentration within the range of the calibrators for each assay, using serum diluent supplied by the assay manufacturer. The use of this diluent was to reduce matrix effects. Skeletal cytosolic extracts were diluted 1:3, and skeletal myofibrillar fractions were diluted 1:2. All skeletal muscle samples were diluted to protein concentrations ϳ20 mg/L before cTnT assay. The calculated limit of detection of the measurement was, thus, 1 g/g of protein.
Total protein was determined by the Bradford method (22 ) . cTnT was measured in serum samples obtained from all ESRD patients at the time of transplant.
The amounts of cTnT in the skeletal muscle samples from the ESRD and the healthy control groups were compared using a Wilcoxon-Mann-Whitney test. This test was also used to compare the CK-MB content. A Kruskal-Wallis ANOVA was used to compare the cTnT content and the CK-MB content of the three muscle sample types, normal skeletal muscle, ESRD skeletal muscle, and LAA muscle.
immunohistochemistry Serial 10-m-thick sections, cut on a cryostat, were mounted on gelatin-coated slides, air dried, and then stored at Ϫ80°C until required for immunohistochemistry. Three slides were prepared for each specimen (with a minimum of five sections per slide). Sections were cut from biopsy material taken from the exterior oblique muscle of healthy patients and patients with ESRD; cardiomyopathic LAA muscle samples were used as positive controls.
Sections were air-dried and then fixed in 40 g/L paraformaldehyde in phosphate-buffered saline (100 mmol/L phosphate, pH 7.4, 8.5 g/L NaCl) for 10 min on ice. The sections were washed in Tris-buffered saline (TBS; 50 mmol/L Tris, pH 7.6, 8.5 g/L NaCl), and endogenous peroxidase was inhibited by incubation for 5 min in 30 mL/L hydrogen peroxide in methanol. After the sections were washed in TBS, they were preincubated for 2 h with 40 mL/L normal horse serum in TBS. For each specimen, the sections of one slide were each incubated overnight at 4°C with anti-cTnT M7 (1:200), anti-cTnT M11-7 (1:200), or diluent alone (40 mL/L normal horse serum in TBS). The sections were then processed at room temperature using the avidin-biotin complex method. Briefly, after washing between each step, the sections were first incubated with biotinylated horse anti-mouse IgG (1:200 in TBS for 2 h; Vector Laboratories) followed by incubation with the avidin-biotin-peroxidase complex (ABC Elite; Vector Laboratories). Bound peroxidase was then visualized by incubation in 0.08 g/L diaminobenzidine tetrahydrochloride, 1 g/L nickel sulfate, and 0.07 mL/L hydrogen peroxide in 50 mmol/L Tris (pH 7.2) for 10 min. The sections were then dehydrated, cleared in xylene, and mounted in preparation for examination by light microscopy.
gel electrophoresis and immunoblotting of cTnT Muscle samples were homogenized in phosphate buffer (200 mmol/L, pH 7.4) containing 100 mL/L glycerol, 5 mmol/L EGTA, and 5 mmol/L ␤-mercaptoethanol in an Ultra-Turrax homogenizer. Tissue homogenates were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Skeletal muscle sample homogenates (15 g of total protein) and LAA muscle sample homogenates (2.5 g of total protein) were loaded on 10% polyacrylamide minigels and electrophoresed according to the Laemmli method (23 ) using the Xcell II precast gel system (Novex). Size-separated proteins were then electrophoretically blotted onto nitrocellulose mem- 
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branes (Amersham Pharmacia Biotech). After electrophoresis, the membranes were blocked with 50 g/L powdered nonfat milk in phosphate-buffered saline overnight at 4°C. The membranes were then incubated with either of the anti-cTnT monoclonal antibodies M11-7 or M7 (Roche). The concentration of all primary antibodies was 2 mg/L. Horseradish peroxidase conjugated to goat anti-mouse IgG (Dako) was then used at a dilution of 1:1000 for the detection of specific binding of the antibodies. All antibodies were diluted in phosphate-buffered saline containing 50 g/L powdered nonfat milk. Immunoblots were developed with ECL TM substrate (Amersham Pharmacia Biotech).
Results
In 19 sera obtained at the time of transplantation the median (range) serum concentration of cTnT was 0.03 (0.00 -0.3) g/L. cTnT was Ͼ0.1 g/L in four samples (21%), which were considered positive for cTnT. One of the patients, with a serum cTnT of 0.3 g/L, died within 5 months of transplantation. There was no correlation between cTnT concentrations and serum creatinine concentrations.
No cTnT was detected by the quantitative assay in 10 of the 19 ESRD skeletal muscle samples. The mean cTnT concentration in the myofibrillar fractions was Ͻ5 g/g of protein for both the ESRD and the control group. cTnT was not detected in any of the cytosolic fractions. In the myofibrillar fractions, there was no statistically significant difference in cTnT concentrations between the healthy controls and the patients with renal failure (P ϭ 0.525). The median (range) cTnT concentrations in the myofibrillar skeletal muscle samples were 0 (0 -9) g/g of protein for controls and 0 (0 -6) g/g of protein for ESRD patients. The median (range) cTnT concentrations in the LAA samples were 38.6 (23.2-81.0) mg/g of protein in the myofibrillar fractions and 2.5 (2.0 -3.6) mg/g of protein in the cytosolic fractions. A positive signal (Ն1 g/g of protein) for cTnT was measured in 9 of the 19 (47%) skeletal muscle samples from patients with ESRD. However, these were all Ͻ7 g/g of protein.
The amounts found in the myofibrillar fractions of the LAA samples were Ͼ6000-fold higher than those found in the comparable skeletal muscle samples. The highest amount of cTnT detected was 6 g/g of protein; this patient did not have a positive serum cTnT. Four of the patients had positive serum cTnT results; of these four, two gave a positive signal of cTnT in skeletal muscle of 1 g/g of protein.
Two of the five (40%) control skeletal muscle samples also gave a positive signal for cTnT. The largest signal for cTnT in skeletal muscle was measured in a muscle sample from a healthy control (9 g/g of protein).
The distribution of CK isoenzymes is summarized in Fig. 1 . There were no significant differences in CK-MB content between the samples from patients with ESRD and the healthy donors (P ϭ 0.270).
There was specific sarcomeric staining for cTnT in human cardiac control tissue, but no positive signal was observed in skeletal muscle taken from healthy kidney donors or from patients with ESRD with either of the two antibodies, M7 and M11-7 (Fig. 2) .
Representative immunoblots of heart, control skeletal muscle, and skeletal muscle from renal failure patients for the two antibodies M11-7 and M7 are shown in Fig. 3 . A major band was observed in extracts from LAA samples, which migrated at a molecular mass of 39 kDa, as detected by both M7 and M11-7. Positive staining was found in all 6 LAA samples analyzed, whereas none of the 24 skeletal muscle samples had 40-kDa (7 ) bands that were immunoreactive with either of the two antibodies.
Discussion
This is the first report of quantitative measurements of cTnT and CK-MB in skeletal muscle extracts from patients with ESRD. This study could not demonstrate any quantitative evidence of increased amounts of cTnT immunoreactivity in skeletal muscle samples taken from patients with ESRD compared with skeletal muscle samples taken from control subjects, as detected by the second-generation cTnT assay from Roche. In addition, we did not detect an increase in the percentage of CK-MB in the total CK found in skeletal muscle. These findings do not support the hypotheses that cTnT and CK-MB are overexpressed, or expressed as fetal isoforms, in noncardiac muscle from patients with renal failure. Qualitative assessments of cTnT expression were made by immunoblotting and immunohistochemistry. The quantitative measurements performed here did not reveal any evidence of abnormal expression of cTnT or overexpression of CK-MB in the skeletal muscle of patients with ESRD.
In heart, the CK-MB isoenzyme accounts for 15-40% of total CK activity, CK-MM being the predominant isoenzyme (24 ) . However, our data showed that CK-MB is the predominant CK isoenzyme. The reasons for this may be that we analyzed muscle taken only from the LAA and not from ventricular myocardium. The only material that was available to us was the LAA. In left ventricular muscle from an explanted cardiomyopathic heart, we found that the CK-MB component was 27% of total CK (25 ) . Applying the same technique and using animal hearts, we also found large differences in CK isoenzyme distribution between the atria and ventricles of the same heart (data not shown). LAA may not be typical myocardial tissue with regard to CK isoenzyme distribution. However, for the purpose of our experiment, we used the LAA samples as a positive control. The LAA data demonstrated that CK-MB was easily detectable when we used the Rapid Electrophoresis system to analyze striated muscle extracts. Trace amounts of cTnT were detected in 9 of the 19 skeletal muscle samples. There was no correlation between the frequency of positive cTnT in serum of these patients and the presence of detectable amounts cTnT in skeletal muscle. These detected amounts of cTnT did not give rise to positive serum results for cTnT. The amounts of cTnT detected in all skeletal muscle samples by this system are subject to a degree of inaccuracy at these very low concentrations. The cTnT assay performed on the ES300 is designed, essentially, for analyzing serum or plasma samples. There is a substantial matrix effect observed with this system. In studies to validate this method, we found that Tris buffer and deionized water gave a positive signal on this system (25 ) . For this reason, all muscle extracts were diluted in assay diluent provided by the manufacturer before analysis. In the case of heart myofibrillar extracts, the samples were diluted by as much as 1:100. Such large dilutions virtually eliminate matrix effects. Skeletal muscle samples contained ϳ20 mg/L protein from the myocyte extract. When we applied the reported limit of detection for this assay of 0.01 g/L (20 ), our detection limit for cTnT was 0.001 mg/g of protein.
Serial dilutions of LAA homogenates showed that the detection limit of the assay was similar to that reported by Muller-Bardorff et al. (20 ) . All of the positive values detected were 0.01-0.5 g/L for the assay of diluted samples. The finding that the number of "positive" samples was not statistically different between the ESRD and donor muscle samples suggests that these positive results may represent analytical inaccuracy or impression. The highest value (0.4 g/L) occurred in a control sample. Although some of the skeletal muscle samples gave a positive signal, this did not correspond to an increase in circulating cTnT concentrations.
Our conclusion that cTnT is not abnormally expressed in skeletal muscle of patients with ESRD is in agreement with the findings of Haller et al. (26 ) , who found no expression of cTnT at the mRNA or protein level in skeletal muscle in patients with ESRD who had positive serum concentrations of cTnT. Our findings are also in agreement with the conclusions of Ricchiuti and coworkers (7, 27 ) that the second-and third-generation cTnT assays would detect only cTnT in circulation that originated from cardiac muscle. We did not reproduce the findings of Ricchiuti and co-workers (7, 27 ) regarding the positive immunoblotting of skeletal muscle of patients with ESRD, using M7 or M11-7. Ricchiuti and co-workers (7, 27 ) reported a particularly high frequency of positive staining when they used the antibody M11-7. However, the results of our immunohistochemistry and analysis of tissue content by the cTnT assay support our negative immunoblots. Our negative findings using the cTnT assay are also in agreement with the conclusions of Ricchiuti et al. (7 ) and the observations of Muller-Bardorff et al. (20 ) that a positive signal produced in the assay format using a combination of the two antibodies, M7 and M11-7, will occur only in response to binding of the adult cTnT isoform.
This study could have been strengthened by the measurement of cTnT expression at the mRNA level. Using reverse transcription-PCR, Messner et al. (28 ) detected mRNA for cTnI and cTnT in 19% of skeletal muscle biopsies taken from patients with various skeletal myopathies, but found neither cTnI nor cTnT in serum from these patients. Ricchiuti and Apple (27 ) detected cTnT mRNA in skeletal muscle biopsies from DMD patients at amounts comparable to those found in heart muscle, but they did not detect cTnT protein when they used laser densitometry to quantify Western blots probed with M11-7 and M7. By contrast, ESRD tissue samples that produced faint bands of mRNA produced large amounts of immunoreactivity with M7 (27 ) . These data clearly demonstrate that detection of mRNA does not always predict the expected pattern of protein expression. In contrast to both Ricchiuti and Apple (27 ) and Messner et al. (28 ) , Haller et al. (26 ) did not detect cTnT at the mRNA or protein level in skeletal muscle, but did find increased cTnT in the plasma of patients with ESRD. This finding suggests that the plasma cTnT did not originate from skeletal muscle (26 ) . We have concluded that the clearest approach to studying cTnT expression in skeletal muscle in relation to circulating concentrations would be to measure cTnT protein in muscle and in circulation.
Ricchiuti et al. (7 ) reported positive immunoreactive bands with M11.7 in Ͻ45% of the samples measured and found bands in Ͻ4.5% with M7. In another study using a smaller sample number (n ϭ 7), the same group found staining in 57% with M11-7 and 29% with M7 (27 ) . These results were not compared with serum cTnT or confirmed by another technique. The authors loaded into each SDS-PAGE well 50 g of protein for both heart extracts and skeletal muscle extracts, whereas we loaded 2.5 and 15 g for heart and skeletal muscle, respectively. Although use of smaller amounts of protein may increase the limit of detection, we considered it inappropriate to use equivalent amounts of the two tissues because heart contains several thousand times more cTnT than skeletal muscle. Because cross-contamination is a common problem with SDS-PAGE, we minimized the amount of heart protein to the amount that would produce a positive signal. Ricchiuti and Apple (27 ) loaded 50 g of total protein for both heart and skeletal muscle extracts and showed a blot for M7 with the equivalent band intensity for both skeletal and heart muscle. Although Western blotting is not a quantitative technique, these findings would suggest that the amounts of cTnT in skeletal and cardiac muscle are similar, which is in conflict with the final conclusions drawn in that report, that cTnT is expressed in small amounts in skeletal muscle. This discrepancy is also illustrated in the earlier report (7 ) in which virtually no cTnT was detected in extracts from cardiac tissue lanes 1 and 2 of Fig. 1. (7 ) . A large band appeared for skeletal muscle, which was larger and more intense than those found in heart. Both of these reports (7, 27 ) used laser densitometry to quantify Western blot data.
There is no consensus that muscle weakness associated with CRF is the result of muscle regeneration, and CRF is not a typical condition associated with muscle regression. The mechanism whereby skeletal muscle weakness is associated with CRF is still poorly understood (29 ) , and numerous potential mechanisms have been reviewed recently (30, 31 ) . It has even been suggested that this muscle weakness is not actually caused by myopathy but by neuropathy (9, 32 ) . Only one report with substantive data supports the theory that the muscle weakness sometimes associated with uremia is related to regenerating muscle (12 ) . Diesel et al. (12 ) compared muscle biopsies from patients with CRF to muscle biopsies from athletes and demonstrated ultrastructural evidence of muscle regeneration (including multinucleated myocytes) in some biopsies from CRF patients (12 ) . In a similar study, however, Bradley et al. (33 ) found that regenerating fibers were exceedingly rare.
There is a similar controversy surrounding the issue of whether cTnT isoforms are present in myopathic skeletal muscle. Several reports have shown that cTnT is not detected in typically regenerating myopathic muscle. The two most established diseases associated with muscle regeneration are DMD and polymyositis. However, cTnT has been shown not to be abnormally expressed in both of these conditions. Ricchiuti and Apple (27 ) did not report that cTnT protein was present in skeletal muscle of patients with DMD, as detected by the antibodies M7 and M11-7; in addition, Bodor et al. (15 ) found quantitatively less cTnT and less CK-MB in skeletal muscle of patients with polymyositis than in healthy adult skeletal muscle. It has also been reported that cTnT was not detected in the skeletal muscle of patients with DMD and the skeletal muscle of the MDX mouse model of DMD by the M7 antibody (34 ) .
Regarding risk stratification among patients with CRF, Porter et al. (35 ) studied 30 CRF patients over a 1-year period and found that cTnT but not cTnI was predictive, whereas other studies found neither cTnI nor cTnT to be of value in risk stratification (36, 37 ) , and another study found that both markers were strong predictors of risk in patients with normal renal function but that their stratification capacity was reduced in CRF patients (38 ) . A more recent study used a much larger number of patients and studied them over a longer period (102 patients over 2 years) than the previous studies and found a single increased cTnT to be strongly predictive of long-term mortality (39 ) .
The negative results reported here contribute to the discussion of whether the skeletal muscle of patients with ESRD expresses the developmental forms of cardiac proteins. Our finding are in agreement with the conclusions of Ricchiuti and co-workers (7, 27 ) , that cTnT detected in the serum of patients with CRF originates from the heart and not from skeletal muscle. Our findings do not support the theory that CRF patients abnormally express cTnT or CK-MB in skeletal muscle.
